Cutaneous T-Cell Lymphoma clinical trials at UC Irvine

1 research study open to eligible people

Showing trials for

  • PTX 100 in Patients With Relapsed/Refractory CTCL

    open to eligible people ages 18 years and up

    This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles, then 21 day cycle thereafter. Subjects will be treated or followed up, if subjects discontinue treatment, for up to 18 months.

    Irvine, California and other locations

Our lead scientists for Cutaneous T-Cell Lymphoma research studies include .

Last updated: